Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate

Author:

Jiang Zhidong123,Feng Bo234,Chen Lu56,Nie Tianqing17,Chen Shizhao8,Wang Li239,Liu Hui2310,Yu Ting23,Zhang Yumin6,Zheng Miao234,Xu Yechun739ORCID,Liu Hong23ORCID,Zang Yi1,Su Haixia73,Zhang Leike611ORCID,Li Jia23489,Zhou Yu12349ORCID

Affiliation:

1. Lingang Laboratory, Shanghai 200031, China

2. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

3. University of Chinese Academy of Sciences, Beijing 100049, China

4. Shenyang Pharmaceutical University, Shenyang 110016, China

5. College of Biological and Pharmaceutical Sciences, China Three Gorges University, Yichang, Hubei 443002, China

6. State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China

7. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

8. School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China

9. School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China

10. Pharmaceutical College of Henan University, Kaifeng 475004, China

11. Hubei Jiangxia Laboratory, Wuhan 430200, China

Funder

National Natural Science Foundation of China

Chinese Academy of Sciences

Qiusuo Outstanding Youth Project of Lingang Laboratory

Publisher

American Chemical Society (ACS)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3